Condition

Pancreatic Ductal Adenocarcinoma clinical trials and research

• 79Clinical trials
• 59NIH research projects
• 2New in 30 days
• 32Countries

Newest Pancreatic Ductal Adenocarcinoma clinical trials

All recruiting trials (79)

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Telisotuzumab Adizutecan with Gemcitabine and Nab-Paclitaxel in Pancreatobiliary Cancers

  This study tests whether adding telisotuzumab adizutecan to standard chemotherapy can help adults with pancreatobiliary cancers see a benefit.

  Recruiting at 7 sites Phase 2 AbbVie · Hattiesburg, Mississippi and 6 other locations · NCT07769502

• GFH276 with Cetuximab or chemotherapy in RAS-mutated solid tumors and PDAC

  This study tests whether GFH276 combined with cetuximab or standard chemotherapy can help adults with advanced solid tumors or pancreatic cancer that carry a RAS mutation.

  Recruiting at 10 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Concord, New South Wales and 16 other locations · NCT07678593

• First-in-human test of BLU-924 for KRAS-mutant advanced cancers

  This trial tests BLU-924 in adults with KRAS-mutant advanced solid tumors, including PDAC, NSCLC, and CRC, to see if it is safe and may help control cancer.

  Recruiting at 3 sites Phase 1/2 Blueprint Medicines Corporation · Sarasota, Florida and 15 other locations · NCT07629960

• IBI3028 in advanced solid tumors

  This phase 1 study tests IBI3028 in adults with unresectable or metastatic solid tumors to see if it is safe and how patients tolerate it.

  Recruiting Phase 1 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tianjin, Tianjin Municipality · NCT07589205

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• IBI343 in combination with chemotherapy for CLDN18.2-positive gastric cancer and pancreatic cancer

  This study tests whether adding IBI343 to standard chemotherapy helps people with CLDN18.2-positive advanced gastric/gastroesophageal junction cancer or pancreatic ductal cancer.

  Recruiting Phase 2 Innovent Biologics (Suzhou) Co. Ltd. · Hangzhou, Zhejiang · NCT07483554

• PET scan using [18F]FPyQCP to image fibroblast activation protein in several cancers

  This test tries a new PET imaging tracer, [18F]FPyQCP, to see if it helps detect colorectal, gastric, pancreatic ductal adenocarcinoma, invasive lobular breast, and epithelial ovarian cancers in adults.

  Recruiting Phase 1/2 Blue Earth Diagnostics · New York, New York and 1 other locations · NCT07432633

• Laparoscopic versus open pancreaticoduodenectomy outcomes

  This trial will test whether laparoscopic (keyhole) pancreaticoduodenectomy leads to fewer complications and faster recovery than open pancreaticoduodenectomy in adults with resectable pancreatic or periampullary tumors.

  Recruiting Minia University · Minya, Minya Governorate · NCT07328607

• Screening to improve early detection of pancreatic cancer in high-risk adults

  This program tests whether repeated contrast-enhanced CT scans combined with blood draws and AI can find pancreatic cancer earlier in people aged 50–85 with recent-onset diabetes and a high ENDPAC score.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07324096

• TTFields plus modFOLFIRINOX for metastatic pancreatic adenocarcinoma

  This trial will test whether adding Tumor Treating Fields (TTFields) to modFOLFIRINOX chemotherapy is safe, tolerable, and helpful for adults with metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 Clinica Universidad de Navarra, Universidad de Navarra · Pamplona, Navarre and 4 other locations · NCT07284277

• Targeted radioligand [177Lu]Lu-DFC413 for advanced pancreatic, lung, breast, and colorectal cancers

  This will test a new targeted radioactive medicine, [177Lu]Lu-DFC413 (with a PET tracer [68Ga]Ga-NNS309), to see if it is safe and shows activity in adults with advanced pancreatic, lung, breast, or colorectal cancer.

  Recruiting at 9 sites Phase 1 Novartis · Princeton, New Jersey and 8 other locations · NCT07261631

• Pretreatment contrast-enhanced MRI with diffusion-weighted imaging to find hidden liver metastases in pancreatic cancer

  This project will test whether adding contrast-enhanced MRI with diffusion-weighted imaging before treatment can find hidden liver metastases in adults newly diagnosed with pancreatic ductal adenocarcinoma.

  Recruiting Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria · Alessandria, Piedmont · NCT07252076

• Total mesopancreas removal to improve outcomes after pancreatic head surgery

  This project will try a standardized total mesopancreas excision during pancreaticoduodenectomy to see if it reduces recurrence and increases disease-free survival in adults with resectable pancreatic head cancer.

  Recruiting Minia University · Minya, Minya Governorate · NCT07232810

• Predicting chemotherapy response in pancreatic cancer using a blood microRNA panel

  This project tests whether a panel of microRNAs in pre-treatment blood can predict response to neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine plus nab‑paclitaxel) in patients with resectable or borderline resectable pancreatic cancer.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07226154

• GEH300079 (68Ga) PET/CT scan to detect peritoneal carcinomatosis in colorectal, gastric, ovarian, and pancreatic cancers (PERISCOPE)

  This will test whether a GEH300079 (68Ga) PET/CT scan can detect peritoneal carcinomatosis in adults with colorectal, gastric, ovarian, or pancreatic ductal adenocarcinoma who have known or suspected peritoneal disease.

  Recruiting Phase 2/3 GE Healthcare · Grand Rapids, Michigan and 1 other locations · NCT07219238

• Maintenance combinatorial myeloid immunotherapy with odetiglucan and mitazalimab for unresectable pancreatic cancer

  This study will try a combination immunotherapy (odetiglucan plus mitazalimab) as maintenance treatment for adults with unresectable pancreatic cancer whose disease has not progressed after 4–6 months of first-line chemotherapy.

  Recruiting Phase 2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07199764

• Monthly alternating NALIRIFOX and gemcitabine plus nab‑paclitaxel for metastatic pancreatic cancer

  This trial will test whether giving NALIRIFOX and gemcitabine plus nab‑paclitaxel in monthly alternating cycles helps adults with metastatic pancreatic ductal adenocarcinoma control their cancer and live longer.

  Recruiting at 7 sites Phase 2 Northwell Health · Bay Shore, New York and 6 other locations · NCT07163273

• Tissue adhesive (Glubran®2) to reinforce pancreaticojejunostomy in soft pancreas

  This trial will test whether adding a tissue adhesive glue (Glubran®2) to the pancreatic-jejunal connection reduces postoperative pancreatic leaks in adults with a soft pancreas undergoing pancreaticoduodenectomy.

  Recruiting Minia University · Minya, Minya Governorate · NCT07155525

• Mesopancreas removal during Whipple surgery for pancreatic head cancer

  This will test whether adding mesopancreatic excision to the Whipple operation helps people with resectable pancreatic head cancer have fewer local recurrences and live longer.

  Recruiting Minia University · Minya, Minya Governorate · NCT07148830

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• Using ctDNA to guide earlier switching from first-line mFOLFIRINOX in metastatic pancreatic cancer

  This will test whether a blood test (ctDNA) can tell if people with metastatic pancreatic cancer are not responding to first-line mFOLFIRINOX soon enough to switch therapies earlier than standard imaging.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07096362

• Finding a suitable dose of ASP5834 for adults with solid tumors

  This trial tests different doses of the experimental drug ASP5834, given alone or with panitumumab, in adults whose advanced solid tumors have certain KRAS mutations to find a safe, tolerable dose.

  Recruiting at 22 sites Phase 1 Astellas Pharma Inc · Santa Monica, California and 21 other locations · NCT07094204

• ASP2138 before surgery, then standard chemotherapy for resectable pancreatic ductal cancer

  This trial will try giving one injection of ASP2138 before surgery and then standard chemotherapy after surgery for adults with CLDN18.2-positive resectable pancreatic ductal adenocarcinoma.

  Recruiting at 3 sites Phase 1 Astellas Pharma Inc · Boston, Massachusetts and 2 other locations · NCT07024615

• VS-7375 for adults with KRAS G12D-mutated advanced solid tumors.

  This trial tests VS-7375, alone and combined with other cancer drugs, in adults with unresectable or metastatic solid tumors that have the KRAS G12D mutation.

  Recruiting at 22 sites Phase 1/2 Verastem, Inc. · Los Angeles, California and 21 other locations · NCT07020221

• DR-0202 for advanced, relapsed, or treatment-resistant carcinomas

  This trial tests DR-0202 in adults with advanced or metastatic carcinomas—such as certain breast, lung, cervical, and prostate cancers—that have relapsed or stopped responding to standard treatments.

  Recruiting at 10 sites Phase 1 Dren Bio · Denver, Colorado and 9 other locations · NCT06999187

• Early multi-gene sequencing to guide therapy in advanced poor-prognosis cancers

  This trial tests whether doing broad multigene sequencing early, with tumor-board input, can help choose targeted treatments for adults with advanced pancreatic, liver, or triple-negative breast cancer.

  Recruiting University Hospital, Lille · Lille · NCT06958224

• Combining endoscopic ultrasound radiofrequency ablation with immunotherapy for advanced pancreatic cancer

  This study is testing a new treatment that combines a special type of ultrasound therapy with chemotherapy and immunotherapy to see if it helps people with advanced pancreatic cancer live better and longer.

  Recruiting Phase 2 The University of Texas Health Science Center, Houston · Houston, Texas · NCT06831136

• Using a new imaging technique to detect cancer-associated fibroblasts in various cancers

  This study is testing a new imaging method to see if it can better detect certain cancer-related cells in people with newly diagnosed esophageal or pancreatic cancer compared to standard imaging techniques.

  Recruiting at 2 sites Phase 2/3 KU Leuven · Edegem and 2 other locations · NCT06782412

• Comparing two methods for preventing pancreatic fistula after surgery

  This study is testing if using a special glue during pancreatic surgery can help prevent serious leaks in the pancreas compared to the usual method for people having surgery for cancer.

  Recruiting Phase 2 Minia University · Minya · NCT06756074

• Targeted therapy using Lead-212 for solid tumors

  This study is testing a new targeted radiation treatment for patients with solid tumors that have a specific protein to see if it can effectively treat their cancer while protecting healthy tissue.

  Recruiting at 16 sites Phase 1/2 Perspective Therapeutics · Los Angeles, California and 15 other locations · NCT06710756

• PTM-101 treatment for pancreatic cancer

  This study is testing a new treatment called PTM-101 combined with chemotherapy to see if it can help people with certain types of pancreatic cancer who haven't had treatment before.

  Recruiting at 9 sites Phase 1 PanTher Therapeutics · Newport Beach, California and 8 other locations · NCT06673017

• AI-based early detection of pancreatic cancer using routine CT scans

  This study is testing an AI system that uses regular CT scans to see if it can help find pancreatic cancer early in people who are at high risk.

  Recruiting at 3 sites Changhai Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT06638866

• Using advanced MRI to assess treatment response in pancreatic cancer

  This study is testing a new MRI technique to see if it can better predict how well treatment works for people with pancreatic cancer.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06600906

• Effect of CT3001 on Advanced Solid Tumors

  This study is testing a new treatment called CT3001 to see if it can help people with advanced solid tumors, like colorectal cancer and pancreatic cancer, who haven't responded to other therapies.

  Recruiting Phase 1/2 Crossignal Therapeutics, Inc. · Houston, Texas · NCT06598007

• Tumor DNA and protein testing to understand pancreatic cancer treatment response

  This trial will test whether measuring tumor DNA and proteins from people with resectable or locally advanced pancreatic ductal adenocarcinoma can be done quickly enough and provide information about how their cancer responds to standard chemotherapy.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT06574620

• Evaluating a new treatment for advanced pancreatic, lung, breast, and colorectal cancers

  This study is testing a new type of radiation treatment for people with advanced pancreatic, lung, breast, and colorectal cancers to see if it is safe and effective.

  Recruiting at 29 sites Phase 1 Novartis · Birmingham, Alabama and 28 other locations · NCT06562192

• Using Lipidica software to screen for pancreatic cancer in high-risk patients

  This study is testing a new software called Lipidica to see if it can help find pancreatic cancer earlier in people who are at high risk because of their genetics or family history.

  Recruiting at 15 sites Lipidica, a.s. · Prague, Czechia and 15 other locations · NCT06549725

• Using a new imaging agent to detect various cancers

  This study is testing a new imaging agent to see if it can better detect certain cancers in adults compared to standard imaging methods.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06503146

• Evaluating RAS(ON) Inhibitors for Gastrointestinal Solid Tumors

  This study is testing new RAS(ON) inhibitors combined with standard treatments to see if they can help people with certain types of gastrointestinal cancers that have RAS mutations.

  Recruiting at 32 sites Phase 1/2 Revolution Medicines, Inc. · Chandler, Arizona and 31 other locations · NCT06445062

• Treatment for advanced gastrointestinal cancers using MK-2870 with or without chemotherapy

  This study is testing whether a new drug called MK-2870, alone or with chemotherapy, can help people with advanced gastrointestinal cancers like colorectal, pancreatic, or biliary tract cancer feel better and improve their treatment outcomes.

  Recruiting at 30 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 54 other locations · NCT06428409

• Early detection of pancreatic cancer using exosome-based biomarkers

  This study is testing a new way to find pancreatic cancer early by looking at tiny particles in the blood that carry specific markers.

  Recruiting at 11 sites City of Hope Medical Center · Phoenix, Arizona and 12 other locations · NCT06388967

• Screening for pancreatic cancer in high-risk individuals

  This study is testing different ways to screen people at high risk for pancreatic cancer to see if early detection can help them live longer.

  Recruiting Masaryk Memorial Cancer Institute · Brno · NCT06330441

• Using AI to find biomarkers for better treatment of pancreatic cancer

  This study is trying to find specific markers in blood and tumor samples from pancreatic cancer patients to see if they can help doctors choose the best treatments for future patients.

  Recruiting at 2 sites Roswell Park Cancer Institute · Buffalo, New York and 1 other locations · NCT06320717

• French test of leftover tumor DNA in the blood after pancreatic cancer surgery

  This will test whether a blood test for tumor DNA after surgery or after adjuvant chemotherapy can find pancreatic cancer patients at high risk of relapse.

  Recruiting University Hospital, Montpellier · Montpellier, Hérault · NCT06287749

• Trimodal prehabilitation program for patients with upper GI and pancreatic cancer

  This study is testing an 8-week program that combines exercise, nutrition help, and mental support for patients with pancreatic or esophageal cancer to see if it can improve their health before surgery.

  Recruiting GERCOR - Multidisciplinary Oncology Cooperative Group · Dijon and 10 other locations · NCT06275737

• Treatment with AZD0901 for advanced solid tumors expressing Claudin18.2

  This study is testing a new treatment called AZD0901 for people with advanced solid tumors that have a specific protein, to see if it works better alone or with other chemotherapy drugs.

  Recruiting at 44 sites Phase 2 AstraZeneca · Orange, California and 51 other locations · NCT06219941

• T cell therapy targeting KRAS G12D in advanced solid tumors

  This trial will test whether autologous T cells engineered to recognize KRAS G12D can help adults with unresectable or metastatic solid tumors who have the matching HLA type.

  Recruiting at 18 sites Phase 1 AstraZeneca · Duarte, California and 17 other locations · NCT06218914

• Registry for patients at high risk for pancreatic cancer

  This study is creating a registry for people at high risk of pancreatic cancer to see if new tests can help catch the disease early.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06151223

• Testing a new drug for adults with advanced solid tumors

  This study is testing a new drug for adults with advanced solid tumors that haven't responded to other treatments to see if it can help them.

  Recruiting at 43 sites Phase 1 Seagen Inc. · Phoenix, Arizona and 47 other locations · NCT06131840

• Evaluating RMC-6291 and RMC-6236 for Advanced KRAS G12C Mutant Solid Tumors

  This study is testing a new combination of drugs to see if they can safely help adults with advanced solid tumors that have a specific KRAS mutation.

  Recruiting at 52 sites Phase 1/2 Revolution Medicines, Inc. · Duarte, California and 55 other locations · NCT06128551

• Screening for pancreatic cancer in high-risk individuals

  This study is testing if combining blood tests and symptom checks with regular screenings can help find pancreatic cancer earlier in people who are at higher risk because of their genetics.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06122896

• Assessing the effects of ABBV-400 on advanced solid tumors

  This study is testing a new drug called ABBV-400 to see if it can help adults with advanced solid tumors like liver, pancreatic, and triple negative breast cancer feel better and manage their disease.

  Recruiting at 47 sites Phase 1 AbbVie · Duarte, California and 53 other locations · NCT06084481

• Combining OT-101 with mFOLFIRINOX for advanced pancreatic cancer

  This study is testing if adding a new treatment called OT-101 to standard chemotherapy can help people with advanced pancreatic cancer live longer and feel better.

  Recruiting at 2 sites Phase 2/3 Mateon Therapeutics · Detroit, Michigan and 1 other locations · NCT06079346

• Using durvalumab and oleclumab before surgery for pancreatic cancer

  This study is testing if giving two immune-boosting treatments before surgery can help people with pancreatic cancer have better outcomes.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT06060405

• Combining radiation therapy with immune-targeting drugs for pancreatic cancer

  This study is testing if combining radiation therapy with immune-targeting drugs can help people with localized pancreatic cancer feel better and improve their treatment outcomes before surgery.

  Recruiting at 5 sites Phase 2 Columbia University · Lake Success, New York and 4 other locations · NCT06048484

• Experimental treatment for advanced solid tumors using AZD5863

  This study is testing a new treatment called AZD5863 to see if it can help adults with advanced solid tumors that have a specific marker in their cancer cells.

  Recruiting at 24 sites Phase 1/2 AstraZeneca · Jacksonville, Florida and 24 other locations · NCT06005493

• Combining NALIRIFOX and Radiation Therapy for Pancreatic Cancer Treatment

  This study is testing if a combination of a new chemotherapy drug called NALIRIFOX, radiation therapy, and a standard chemotherapy drug can help people with locally advanced pancreatic cancer before they have surgery.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05851924

• Registry to track outcomes in patients with KRAS G12R altered advanced pancreatic cancer treated with MEK inhibitors

  This study is tracking how well different combination treatments using MEK inhibitors work for people with advanced pancreatic cancer that has a specific KRAS mutation.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05630989

• Treatment of advanced gastric, pancreatic, and biliary tract cancers with Spevatamig

  This study is testing a new treatment called Spevatamig for people with advanced stomach, pancreatic, or bile duct cancers to see if it works better alone or with other cancer therapies.

  Recruiting at 10 sites Phase 1/2 Phanes Therapeutics · Duarte, California and 10 other locations · NCT05482893

• Evaluating Mavrostobart for advanced lung and pancreatic cancer

  This study is testing a new treatment called Mavrostobart to see if it can help people with advanced lung and pancreatic cancer by boosting their immune response against tumors.

  Recruiting at 5 sites Phase 1/2 Phanes Therapeutics · Huntersville, North Carolina and 5 other locations · NCT05431270

• Liquid biopsy to detect AXL-positive circulating tumor cells in pancreatic cancer

  This test tries a blood-based liquid biopsy to see if AXL-positive circulating tumor cells can be found in adults with newly diagnosed metastatic pancreatic cancer who have not yet received treatment.

  Recruiting University Hospital, Montpellier · Montpellier · NCT05346536

• Adjuvant therapy for resected PDAC guided by a transcriptomic signature

  In people with pancreatic ductal adenocarcinoma that has been surgically removed, this study tests whether choosing oxaliplatin- or gemcitabine-based chemotherapy based on a treatment-specific transcriptomic signature works better than choosing based on standard clinical criteria.

  Recruiting Phase 3 University Hospital Heidelberg · Aachen and 32 other locations · NCT05314998

• Investigating how pancreatic cancer uses nutrients to survive

  This study is testing how pancreatic cancer uses sugar to survive by looking at tissue samples from patients during surgery to see if it behaves differently than normal pancreatic cells.

  Recruiting at 2 sites Rutgers, The State University of New Jersey · Livingston, New Jersey and 1 other locations · NCT05296421

• Assessing JPI-547 with chemotherapy for advanced pancreatic cancer

  This study is testing a new drug called JPI-547 combined with chemotherapy to see if it can safely help people with advanced pancreatic cancer.

  Recruiting at 4 sites Phase 1/2 Onconic Therapeutics Inc. · Gyeonggi-do and 3 other locations · NCT05257993

• Combining Nab-Paclitaxel and Gemcitabine with SBP-101 for Pancreatic Cancer

  This study is testing if adding a new treatment called SBP-101 to the standard drugs nab-paclitaxel and gemcitabine can help people with untreated metastatic pancreatic cancer live longer and feel better.

  Recruiting at 77 sites Phase 2/3 Panbela Therapeutics, Inc. · Hot Springs, Arkansas and 92 other locations · NCT05254171

• Combination of FOLFIRINOX and Pembrolizumab followed by surgery for resectable pancreatic cancer

  This study is testing a combination of chemotherapy and an immune therapy to see if it can help people with early-stage pancreatic cancer before they have surgery.

  Recruiting at 3 sites Phase 2 Baylor College of Medicine · Houston, Texas and 2 other locations · NCT05132504

• Evaluating the safety of AB122 in patients with advanced solid tumors

  This study is testing a new drug called AB122 to see if it's safe for people with advanced solid tumors like pancreatic, colorectal, lung, and gastric cancers.

  Recruiting at 9 sites Phase 1 Taiho Pharmaceutical Co., Ltd. · Aichi and 8 other locations · NCT04999761

• Research on early detection of pancreatic cancer

  This study is trying to find better ways to detect pancreatic cancer early by looking at people who are at high risk because of their family history or genetics.

  Recruiting at 57 sites Arbor Research Collaborative for Health · Phoenix, Arizona and 61 other locations · NCT04970056

• Combining Immuncell-LC with Gemcitabine for Pancreatic Cancer Treatment

  This study is testing if adding a new immunotherapy called Immuncell-LC to the chemotherapy drug gemcitabine can help people with operable pancreatic cancer do better than with gemcitabine alone.

  Recruiting Phase 3 GC Cell Corporation · Seoul, Daehak-ro, Jongno-gu · NCT04969731

• Tegavivint treatment for recurrent or refractory solid tumors in children

  This study tests if a new intravenous medication called tegavivint can help children with tough-to-treat solid tumors, like Ewing sarcoma and desmoid tumors, by finding the right dose and seeing how well it works.

  Recruiting at 19 sites Phase 1/2 Children's Oncology Group · Birmingham, Alabama and 20 other locations · NCT04851119

• Treatment of advanced or metastatic solid tumors with ART0380

  This study is testing a new drug called ART0380 to see if it can safely help people with advanced solid tumors that have specific DNA repair issues, either on its own or with other chemotherapy drugs.

  Recruiting at 62 sites Phase 1/2 Artios Pharma Ltd · Birmingham, Alabama and 87 other locations · NCT04657068

• Investigating microRNA for diagnosing and treating pancreatic cancer

  This study is testing whether certain tiny molecules in the blood can help doctors diagnose pancreatic cancer earlier and see how well treatments are working for patients.

  Recruiting Nuvance Health · Norwalk, Connecticut · NCT04406831

• Registry for pancreatic cysts at UCSF

  This study is setting up a registry to track patients with pancreatic cysts to see how these cysts change over time and to help doctors make better treatment decisions.

  Recruiting University of California, San Francisco · San Francisco, California · NCT04291651

• Treatment for metastatic cancer with BRCA or PALB2 mutations using chemotherapy and stem cells

  This study is testing a new treatment combining chemotherapy and stem cells for people with metastatic pancreatic or breast cancer who have BRCA or PALB2 mutations to see if it is safe and effective.

  Recruiting Phase 1 General Oncology, Inc. · Boston, Massachusetts and 1 other locations · NCT04150042

• T cell therapy targeting KRAS G12V mutation for advanced pancreatic cancer

  This study is testing a new T cell therapy that uses patients' own immune cells to target a specific mutation in advanced pancreatic cancer to see if it can help them fight the disease.

  Recruiting Phase 1/2 Changhai Hospital · Shanghai · NCT04146298

• iExosomes for metastatic pancreatic cancer with KRAS G12D mutation

  This trial will test if iExosomes — tiny vesicles made from mesenchymal stromal cells that carry KRAS G12D-targeting siRNA — can help people with metastatic pancreatic ductal adenocarcinoma who have the KRAS G12D mutation.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT03608631

NIH-funded research (newest 40 of 59)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer

  This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.

  NIH research Utah State Higher Education System--University of Utah · Salt Lake City, United States · NIH-11455114

• TREM2+ macrophages and liver metastases in pancreatic cancer

  Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.

  NIH research Washington University · Saint Louis, United States · NIH-11452084

• Protein S could slow pancreatic cancer and blood clots

  A potential treatment study looks at restoring a natural blood protein, Protein S, to help people with pancreatic cancer by slowing tumor growth and reducing dangerous clots.

  NIH research Lsu Health Sciences Center · New Orleans, United States · NIH-11450513

• In vivo B7-H3 CAR-T cells for pancreatic cancer therapy

  A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.

  NIH research Mucommune, LLC · Morrisville, UNITED STATES · NIH-11416630

• Metabolic changes in pancreatic cancer when treated with crisantaspase

  Aims to understand how pancreatic cancer cells adapt their metabolism when treated with crisantaspase to inform better treatment strategies for patients.

  NIH research West Virginia University · Morgantown, United States · NIH-11413687

• New combination therapy for pancreatic cancer in animals

  A new therapy designed to weaken the tumor’s protective surroundings and boost treatment effects in pancreatic cancer models.

  NIH research Proda Biotech, LLC · Marietta, United States · NIH-11409793

• Novel combo therapy using oncolytic adenovirus and immune drugs for pancreatic cancer

  Aims to combine an oncolytic virus with immune therapies to help shrink pancreatic tumors before surgery and keep them from coming back.

  NIH research Uinta Bio, INC. · Park City, UNITED STATES · NIH-11407396

• 5mC and 5hmC DNA blood biomarkers for early detection of pancreatic cancer

  A blood-based test using DNA modifications (5mC and 5hmC) is being developed to detect pancreatic cancer early, aiming to catch the disease before it advances.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11400457

• Improving Early PDAC Detection Using Electronic Medical Records

  A patient-centered approach to use electronic health records to spot signs of pancreatic cancer early, especially in people with new or changing blood sugar levels.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11399853

• Mucin-1 targeted nanoparticles delivering chemotherapy for pancreatic cancer

  A new targeted nanoparticle system is being developed to deliver chemotherapy directly to pancreatic cancer cells in order to improve treatment outcomes.

  NIH research University of North Carolina Charlotte · Charlotte, United States · NIH-11380928

• Making pancreatic cancer early by intercepting the disease before it progresses

  A researchers are testing strategies to catch and stop pancreatic cancer early, aiming to prevent it from becoming deadly.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11366831

• Understanding how immune-friendly cancer-associated fibroblasts shape pancreatic cancer

  Aimed at mapping a special type of support cell in pancreatic cancer to see how it helps the tumor hide from the immune system and resist treatment.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11366758

• Overcoming therapeutic resistance in pancreatic cancer

  Researchers are tackling why pancreatic ductal adenocarcinoma often outsmarts treatments and exploring new ways to overcome it to help patients live longer.

  NIH research Salk Institute for Biological Studies · La Jolla, UNITED STATES · NIH-11364210

• Collagen-targeted PET imaging to guide pancreatic cancer treatment planning

  A doctor-scientist at a major hospital is testing a new PET imaging probe to better map fibrosis in pancreatic cancer so treatments can be planned more accurately.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11353991

• Early detection biomarkers for pancreatic cancer and high-risk lesions

  A study at Johns Hopkins aims to find blood-based biomarkers that could flag pancreatic cancer and high-risk precursor lesions early, especially in people already under surveillance.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11348928

• How PPARD activity helps early pancreatic lesions become pancreatic cancer

  This research looks at whether high PPARD activity in the pancreas helps precancerous PanIN lesions progress to pancreatic ductal adenocarcinoma in adults at risk.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11266192

• Combining a targeted tumor‑ablation technique with immunotherapy for pancreatic cancer

  Seeing if pairing irreversible electroporation (a focused tumor‑destroying procedure) with immune‑boosting drugs can help people with pancreatic ductal adenocarcinoma respond better to treatment.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11263681

• How HIF2 in pancreatic tumor-supporting cells affects cancer growth

  This project tests whether blocking a low-oxygen protein called HIF2 in the supportive fibroblast cells around pancreatic tumors can slow tumor growth and help people with pancreatic cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11248738

• Blocking a protein (HNF1A) that helps pancreatic cancer resist treatment

  Researchers are trying to block a protein called HNF1A to make drug-resistant pancreatic cancer cells more vulnerable to treatment.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11238562

• Investigating how a specific protein affects pancreatic cancer growth and spread

  This study is looking at a protein called RCC1 to see how it affects pancreatic cancer cells, with the hope that understanding its role could help develop new treatments for patients facing this tough disease.

  NIH research Wayne State University · Detroit, United States · NIH-11228868

• Improving engineered T-cell therapy for pancreatic cancer

  Engineered T cells that target the protein mesothelin are being developed to shrink tumors and change the tumor environment for people with pancreatic cancer.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11211991

• Understanding how HIF2 affects pancreatic cancer growth

  This study is looking at how a protein called HIF2 in certain cells around pancreatic cancer tumors might help the cancer survive treatment by making the area low in oxygen, and researchers want to see if getting rid of HIF2 can slow down the tumor's growth and improve outcomes for patients with this tough cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11210731

• PET imaging of tumor-supporting fibroblast cells in pancreatic cancer using 68Ga‑FAPI‑46

  This project uses a PET imaging tracer called 68Ga‑FAPI‑46 to reveal fibroblast cells that support pancreatic tumors in people with pancreatic ductal adenocarcinoma.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11190830

• How pancreatic cancer and nearby stromal cells scavenge nutrients

  Researchers are looking at how pancreatic cancer cells and the fibroblasts around them take up and break down proteins to survive when key nutrients are low.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11187016

• AI to find early signs of pancreatic cancer on routine CT scans

  Uses artificial intelligence to look at routine abdominal CT scans and medical information to find people likely to develop pancreatic cancer within three years.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11172502

• Finding new ways to treat pancreatic cancer

  This research aims to understand why pancreatic cancer treatments often stop working, so we can develop more effective therapies for patients.

  NIH research Salk Institute for Biological Studies · La Jolla, UNITED STATES · NIH-11167603

• How pancreatic cancer cells scavenge nutrients when starving

  This work looks at how pancreatic cancer cells increase protein uptake to survive low-nutrient conditions, aiming to help people with pancreatic cancer.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11145627

• Improving engineered T cell therapy for pancreatic cancer

  A new engineered T cell approach aims to attack pancreatic cancer and its protective tumor environment to help people with advanced pancreatic cancer.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11143879

• MUC1-targeted nanoparticles that deliver two chemotherapy drugs to pancreatic cancer

  A targeted nanoparticle is designed to carry gemcitabine and cisplatin into MUC1-positive pancreatic tumors to try to improve treatment for people with pancreatic ductal adenocarcinoma.

  NIH research University of North Carolina Charlotte · Charlotte, United States · NIH-11143710

• New Imaging to Guide Pancreatic Cancer Treatment

  This project looks for a better way to see how pancreatic cancer responds to treatment using a special imaging scan.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11125951

• Finding early signs of pancreatic cancer and high-risk growths

  This work aims to discover new blood tests that can find pancreatic cancer and precancerous growths at their earliest stages, especially for people at higher risk.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11089571

• Investigating how TLR2 affects immune response in pancreatic cancer

  This study is looking at how a specific protein affects the immune system's ability to fight pancreatic cancer, with the hope of finding new ways to improve treatments for patients battling this disease.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11085061

• Targeting a specific protein to improve treatment for pancreatic cancer

  This study is looking at how blocking a protein called PIKfyve might help fight pancreatic cancer by making it harder for the cancer to survive when there aren't many nutrients, and it hopes to find new ways to improve treatment for patients.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11071075

• Understanding how immune activation changes the environment around pancreatic cancer cells

  This study is looking at how the surroundings of pancreatic cancer cells affect the immune system and aims to find ways to make current treatments work better for patients by understanding the role of certain cells in that environment.

  NIH research Washington University · Saint Louis, United States · NIH-11067055

• Understanding how pancreatic cancer spreads through lymph nodes

  This study is looking at how pancreatic cancer spreads to lymph nodes and how certain immune cells there might help the cancer survive, with the goal of finding ways to boost the body's natural defenses against the disease.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11065840

• Investigating how PPARD affects the progression of pancreatic cancer

  This study is looking at how certain diets and genetic changes might help us understand how early signs of pancreatic cancer develop into the disease, using mice to find new ways to prevent or treat pancreatic cancer.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11036308

• Understanding how immunotherapy works in pancreatic cancer

  This study is looking at why some people with pancreatic cancer benefit from immunotherapy while others don’t, and it aims to find better treatment combinations that can help boost the immune system's fight against this tough cancer.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11035117

• Investigating how HIF2 affects pancreatic cancer growth

  This study is looking at how a specific protein called HIF2 affects the growth of pancreatic cancer and the surrounding support cells, with the hope that understanding this could help create better treatments for patients battling this tough cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11030249

• Using electrical pulses to enhance cancer immunotherapy for pancreatic cancer

  This study is looking at how using electrical pulses to destroy pancreatic cancer cells, along with immune therapy, might help make the cancer more responsive to treatment and improve survival for patients with pancreatic ductal adenocarcinoma.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11017042

• Using AI to predict pancreatic cancer risk in African Americans from CT scans

  This study is using advanced computer technology to look at CT scans and help find out which African Americans might be at higher risk for pancreatic cancer in the next ten years, so that doctors can catch it early and improve treatment options.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11014899

Related topics

Quick answers

How many Pancreatic Ductal Adenocarcinoma clinical trials are recruiting right now?

79, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 32 countries. The most sites are in United States (53 trials), Spain (14 trials), France (13 trials), China (10 trials), Japan (9 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 18, Phase 1: 15, Phase 2: 13, Phase 2/3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →